{"count": 2, "results": [{"_id": "34180715", "pmid": 34180715, "title": "Therapeutic effects of lisinopril and empagliflozin in a mouse model of hypertension-accelerated diabetic kidney disease.", "journal": "Am J Physiol Renal Physiol", "authors": ["Østergaard MV", "Secher T", "Christensen M", "Salinas CG", "Roostalu U", "Skytte JL", "Rune I", "Hansen HH", "Jelsing J", "Vrang N", "Fink LN"], "date": "2021-08-01T00:00:00Z", "doi": "10.1152/ajprenal.00154.2021", "meta_date_publication": "2021 Aug 1", "meta_volume": "321", "meta_issue": "2", "meta_pages": "F149-F161", "score": 50254.027, "text_hl": "Total glomerular numbers and individual glomerular volume were evaluated by whole kidney three-dimensional imaging analysis. db/db UNx-ReninAAV @SPECIES_10090 @@@mice@@@ developed hallmarks of progressive @DISEASE_Diabetic_Nephropathies @DISEASE_MESH:D003928 @@@DKD@@@ characterized by severe @DISEASE_Albuminuria @DISEASE_MESH:D000419 @@@albuminuria@@@, advanced @DISEASE_Glomerulonephritis @DISEASE_MESH:D005921 @@@glomerulosclerosis@@@, and @DISEASE_Hypertrophy @DISEASE_MESH:D006984 @@@glomerular hypertrophy@@@. @<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@Lisinopril@@@ significantly improved @DISEASE_Albuminuria @DISEASE_MESH:D000419 @@@albuminuria@@@, @DISEASE_Glomerulonephritis @DISEASE_MESH:D005921 @@@glomerulosclerosis@@@, @<m>DISEASE_Nephritis_Interstitial</m> @DISEASE_MESH:D009395 @@@tubulointerstitial injury@@@, and @DISEASE_Inflammation @DISEASE_MESH:D007249 @@@inflammation@@@. ", "citations": {"NLM": "Østergaard MV, Secher T, Christensen M, Salinas CG, Roostalu U, Skytte JL, Rune I, Hansen HH, Jelsing J, Vrang N, Fink LN. Therapeutic effects of lisinopril and empagliflozin in a mouse model of hypertension-accelerated diabetic kidney disease. Am J Physiol Renal Physiol. 2021 Aug 1;321(2):F149-F161. PMID: 34180715", "BibTeX": "@article{34180715, title={Therapeutic effects of lisinopril and empagliflozin in a mouse model of hypertension-accelerated diabetic kidney disease.}, author={Østergaard MV and Secher T and Christensen M and Salinas CG and Roostalu U and Skytte JL and Rune I and Hansen HH and Jelsing J and Vrang N and Fink LN}, journal={Am J Physiol Renal Physiol}, volume={321}, number={2}, pages={F149-F161}}"}}, {"_id": "19952417", "pmid": 19952417, "title": "Combination therapy with SMP-534 and an angiotensin-converting enzyme inhibitor provides additional renoprotection in 5/6 nephrectomized rats.", "journal": "Biol Pharm Bull", "authors": ["Tsujimura T", "Nagamine J", "Sugaru E", "Ono-Kishino M", "Tokunaga T", "Kitoh M", "Nagata R", "Nakagawa T", "Taiji M"], "date": "2009-12-01T00:00:00Z", "doi": "10.1248/bpb.32.1991", "meta_date_publication": "2009 Dec", "meta_volume": "32", "meta_issue": "12", "meta_pages": "1991-6", "score": 50057.83, "text_hl": "In addition, combination therapy with @CHEMICAL_SMP_534 @CHEMICAL_MESH:C505358 @@@SMP-534@@@ and @<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@lisinopril@@@ significantly decreased extracellular matrix (ECM) accumulation in renal glomeruli and @<m>DISEASE_Nephritis_Interstitial</m> @DISEASE_MESH:D009395 @@@tubulointerstitial injury@@@. ", "citations": {"NLM": "Tsujimura T, Nagamine J, Sugaru E, Ono-Kishino M, Tokunaga T, Kitoh M, Nagata R, Nakagawa T, Taiji M. Combination therapy with SMP-534 and an angiotensin-converting enzyme inhibitor provides additional renoprotection in 5/6 nephrectomized rats. Biol Pharm Bull. 2009 Dec;32(12):1991-6. PMID: 19952417", "BibTeX": "@article{19952417, title={Combination therapy with SMP-534 and an angiotensin-converting enzyme inhibitor provides additional renoprotection in 5/6 nephrectomized rats.}, author={Tsujimura T and Nagamine J and Sugaru E and Ono-Kishino M and Tokunaga T and Kitoh M and Nagata R and Nakagawa T and Taiji M}, journal={Biol Pharm Bull}, volume={32}, number={12}, pages={1991-6}}"}}]}